Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 1/2007

01.01.2007 | Symposium Paper

Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands

verfasst von: Rafael Solana, Javier G. Casado, Elena Delgado, Olga DelaRosa, Juan Marín, Esther Durán, Graham Pawelec, Raquel Tarazona

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

In recent years, studies on the molecular and cellular mechanisms of immune responses against melanoma have contributed to a better understanding of how these tumours can be recognised by cytotoxic cells and the mechanisms they have developed to escape from innate and adaptive immunity. Lysis of melanoma cells by natural killer (NK) cells and cytolytic T cells is the result of a fine balance between signals transmitted by activating and inhibitory receptors. In addition to the T cell receptor, these were initially described as NK cell-associated receptors (NKRs) and were later also found on subsets of T lymphocytes, particularly effector-memory and terminally differentiated CD8 T cells. An increase of NKR+CD8+ T cells has been found in melanoma patients, correlating with the expansion of differentiated effector CD8+CD28null CD27null T cells. NKRs can regulate the lysis of target cells expressing appropriate ligands. Activating receptors recognise ligands on tumours whereas inhibitory receptors are specific for MHC class I antigens and sense missing self. Altered expression of MHC class I antigens is frequently found on melanoma cells, preventing recognition by specific cytolytic T cells but favouring NK cell recognition. Changes in the expression of NKR-ligands in melanoma contribute in explaining the differences in the capacity of cytotoxic immune cells to control melanoma growth and dissemination.
Literatur
1.
Zurück zum Zitat Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ (2003) NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 24:603CrossRefPubMed Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ (2003) NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 24:603CrossRefPubMed
2.
Zurück zum Zitat Aldemir H, Prod’homme V, Dumaurier MJ, Retiere C, Poupon G, Cazareth J, Bihl F, Braud VM (2005) Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol 175:7791PubMed Aldemir H, Prod’homme V, Dumaurier MJ, Retiere C, Poupon G, Cazareth J, Bihl F, Braud VM (2005) Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J Immunol 175:7791PubMed
3.
Zurück zum Zitat Alegre ML, Frauwirth KA, Thompson CB (2001) T-cell regulation by CD28 and CTLA-4. Nature Rev Immunol 1:220CrossRef Alegre ML, Frauwirth KA, Thompson CB (2001) T-cell regulation by CD28 and CTLA-4. Nature Rev Immunol 1:220CrossRef
4.
Zurück zum Zitat Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53:904CrossRefPubMed Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53:904CrossRefPubMed
5.
Zurück zum Zitat Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O (2001) Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 31:2680CrossRefPubMed Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O (2001) Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 31:2680CrossRefPubMed
6.
Zurück zum Zitat Ashton-Rickardt PG (2005) The granule pathway of programmed cell death. Crit Rev Immunol 25:161CrossRefPubMed Ashton-Rickardt PG (2005) The granule pathway of programmed cell death. Crit Rev Immunol 25:161CrossRefPubMed
7.
Zurück zum Zitat Bakker AB, Wu J, Phillips JH, Lanier LL (2000) NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum Immunol 61:18CrossRefPubMed Bakker AB, Wu J, Phillips JH, Lanier LL (2000) NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum Immunol 61:18CrossRefPubMed
8.
Zurück zum Zitat Becker JC, Vetter CS, Schrama D, Brocker EB, thor Straten P (2000) Differential expression of CD28 and CD94/NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node. Eur J Immunol 30:3699CrossRefPubMed Becker JC, Vetter CS, Schrama D, Brocker EB, thor Straten P (2000) Differential expression of CD28 and CD94/NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node. Eur J Immunol 30:3699CrossRefPubMed
9.
Zurück zum Zitat Bertone S, Schiavetti F, Bellomo R, Vitale C, Ponte M, Moretta L, Mingari MC (1999) Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur J Immunol 29:23CrossRefPubMed Bertone S, Schiavetti F, Bellomo R, Vitale C, Ponte M, Moretta L, Mingari MC (1999) Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur J Immunol 29:23CrossRefPubMed
10.
Zurück zum Zitat Biassoni R, Cantoni C, Falco M, Verdiani S, Bottino C, Vitale M, Conte R, Poggi A, Moretta A, Moretta L (1996) The human leukocyte antigen (HLA)-C-specific “activatory” or “inhibitory” natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med 183:645CrossRefPubMed Biassoni R, Cantoni C, Falco M, Verdiani S, Bottino C, Vitale M, Conte R, Poggi A, Moretta A, Moretta L (1996) The human leukocyte antigen (HLA)-C-specific “activatory” or “inhibitory” natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med 183:645CrossRefPubMed
11.
Zurück zum Zitat Bloushtain N, Qimron U, Bar-Ilan A, Hershkovitz O, Gazit R, Fima E, Korc M, Vlodavsky I, Bovin NV, Porgador A (2004) Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol 173:2392PubMed Bloushtain N, Qimron U, Bar-Ilan A, Hershkovitz O, Gazit R, Fima E, Korc M, Vlodavsky I, Bovin NV, Porgador A (2004) Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol 173:2392PubMed
12.
Zurück zum Zitat Borrego F, Kabat J, Kim DK, Lieto L, Maasho K, Pena J, Solana R, Coligan JE (2002) Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 38:637CrossRefPubMed Borrego F, Kabat J, Kim DK, Lieto L, Maasho K, Pena J, Solana R, Coligan JE (2002) Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 38:637CrossRefPubMed
13.
Zurück zum Zitat Bottino C, Castriconi R, Moretta L, Moretta A (2005) Cellular ligands of activating NK receptors. Trends Immunol 26:221CrossRefPubMed Bottino C, Castriconi R, Moretta L, Moretta A (2005) Cellular ligands of activating NK receptors. Trends Immunol 26:221CrossRefPubMed
14.
Zurück zum Zitat Bottino C, Moretta L, Moretta A (2006) NK cell activating receptors and tumor recognition in humans. Curr Top Microbiol Immunol 298:175PubMed Bottino C, Moretta L, Moretta A (2006) NK cell activating receptors and tumor recognition in humans. Curr Top Microbiol Immunol 298:175PubMed
15.
Zurück zum Zitat Bottino C, Moretta L, Pende D, Vitale M, Moretta A (2004) Learning how to discriminate between friends and enemies, a lesson from Natural Killer cells. Mol Immunol 41:569CrossRefPubMed Bottino C, Moretta L, Pende D, Vitale M, Moretta A (2004) Learning how to discriminate between friends and enemies, a lesson from Natural Killer cells. Mol Immunol 41:569CrossRefPubMed
16.
Zurück zum Zitat Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F (2003) Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 52:1PubMed Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F (2003) Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 52:1PubMed
17.
Zurück zum Zitat Cantoni C, Biassoni R, Pende D, Sivori S, Accame L, Pareti L, Semenzato G, Moretta L, Moretta A, Bottino C (1998) The activating form of CD94 receptor complex: CD94 covalently associates with the Kp39 protein that represents the product of the NKG2-C gene. Eur J Immunol 28:327CrossRefPubMed Cantoni C, Biassoni R, Pende D, Sivori S, Accame L, Pareti L, Semenzato G, Moretta L, Moretta A, Bottino C (1998) The activating form of CD94 receptor complex: CD94 covalently associates with the Kp39 protein that represents the product of the NKG2-C gene. Eur J Immunol 28:327CrossRefPubMed
18.
Zurück zum Zitat Carreno BM, Collins M (2002) The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 20:29CrossRefPubMed Carreno BM, Collins M (2002) The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 20:29CrossRefPubMed
19.
Zurück zum Zitat Casado JG, Soto R, DelaRosa O, Peralbo E, Muñoz-Villanueva MC, Rioja L, Peña J, Solana R, arazona R (2005) CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype. Cancer Immunol Immunother 54:1162CrossRefPubMed Casado JG, Soto R, DelaRosa O, Peralbo E, Muñoz-Villanueva MC, Rioja L, Peña J, Solana R, arazona R (2005) CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype. Cancer Immunol Immunother 54:1162CrossRefPubMed
20.
21.
Zurück zum Zitat Cerwenka A, Lanier LL (2003) NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61:335CrossRefPubMed Cerwenka A, Lanier LL (2003) NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61:335CrossRefPubMed
22.
Zurück zum Zitat Colucci F, Caligiuri MA, Di Santo JP (2003) What does it take to make a natural killer? Nat Rev Immunol 3:413CrossRefPubMed Colucci F, Caligiuri MA, Di Santo JP (2003) What does it take to make a natural killer? Nat Rev Immunol 3:413CrossRefPubMed
23.
Zurück zum Zitat Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633CrossRefPubMed Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633CrossRefPubMed
24.
Zurück zum Zitat Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA (2004) NK cell and DC interactions. Trends Immunol 25:47CrossRefPubMed Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA (2004) NK cell and DC interactions. Trends Immunol 25:47CrossRefPubMed
25.
Zurück zum Zitat Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ (2001) ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123CrossRefPubMed Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ (2001) ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123CrossRefPubMed
26.
Zurück zum Zitat DelaRosa O, Tarazona R, Casado JG, Alonso C, Ostos B, Pena J, Solana R (2002) Valpha24+ NKT cells are decreased in elderly humans. Exp Gerontol 37:213CrossRefPubMed DelaRosa O, Tarazona R, Casado JG, Alonso C, Ostos B, Pena J, Solana R (2002) Valpha24+ NKT cells are decreased in elderly humans. Exp Gerontol 37:213CrossRefPubMed
27.
Zurück zum Zitat Effros RB (1997) Loss of CD28 expression on T lymphocytes: a marker of replicative senescence. Dev Comp Immunol 21:471CrossRefPubMed Effros RB (1997) Loss of CD28 expression on T lymphocytes: a marker of replicative senescence. Dev Comp Immunol 21:471CrossRefPubMed
28.
Zurück zum Zitat Ehrlich LI, Ogasawara K, Hamerman JA, Takaki R, Zingoni A, Allison JP, Lanier LL (2005) Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol 174:1922PubMed Ehrlich LI, Ogasawara K, Hamerman JA, Takaki R, Zingoni A, Allison JP, Lanier LL (2005) Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol 174:1922PubMed
29.
Zurück zum Zitat Ferrone S, Finerty JF, Jaffee EM, Nabel GJ (2000) How much longer will tumour cells fool the immune system? Immunol Today 21:70CrossRefPubMed Ferrone S, Finerty JF, Jaffee EM, Nabel GJ (2000) How much longer will tumour cells fool the immune system? Immunol Today 21:70CrossRefPubMed
30.
Zurück zum Zitat Garrity D, Call ME, Feng J, Wucherpfennig KW (2005) The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci USA 102:7641CrossRefPubMed Garrity D, Call ME, Feng J, Wucherpfennig KW (2005) The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci USA 102:7641CrossRefPubMed
31.
Zurück zum Zitat Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734CrossRefPubMed Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734CrossRefPubMed
32.
Zurück zum Zitat Guerra N, Benlhassan K, Carayol G, Guillard M, Pardoux C, Chouaib S, Caignard A (1999) Effect of tumor growth factor-beta on NK receptor expression by allostimulated CD8+ T lymphocytes. Eur Cytokine Netw 10:357PubMed Guerra N, Benlhassan K, Carayol G, Guillard M, Pardoux C, Chouaib S, Caignard A (1999) Effect of tumor growth factor-beta on NK receptor expression by allostimulated CD8+ T lymphocytes. Eur Cytokine Netw 10:357PubMed
33.
Zurück zum Zitat Held W, Coudert JD, Zimmer J (2003) The NK cell receptor repertoire: formation, adaptation and exploitation. Curr Opin Immunol 15:233CrossRefPubMed Held W, Coudert JD, Zimmer J (2003) The NK cell receptor repertoire: formation, adaptation and exploitation. Curr Opin Immunol 15:233CrossRefPubMed
34.
Zurück zum Zitat Huard B, Karlsson L (2000) A subpopulation of CD8+ T cells specific for melanocyte differentiation antigens expresses killer inhibitory receptors (KIR) in healthy donors: evidence for a role of KIR in the control of peripheral tolerance. Eur J Immunol 30:1665CrossRefPubMed Huard B, Karlsson L (2000) A subpopulation of CD8+ T cells specific for melanocyte differentiation antigens expresses killer inhibitory receptors (KIR) in healthy donors: evidence for a role of KIR in the control of peripheral tolerance. Eur J Immunol 30:1665CrossRefPubMed
35.
Zurück zum Zitat Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JPJ, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104:170CrossRefPubMed Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JPJ, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104:170CrossRefPubMed
36.
Zurück zum Zitat Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, De Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199CrossRefPubMed Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, De Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199CrossRefPubMed
37.
Zurück zum Zitat Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB (2005) Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 42:535CrossRefPubMed Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB (2005) Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 42:535CrossRefPubMed
38.
Zurück zum Zitat Kammertoens T, Schuler T, Blankenstein T (2005) Immunotherapy: target the stroma to hit the tumor. Trends Mol Med 11:225CrossRefPubMed Kammertoens T, Schuler T, Blankenstein T (2005) Immunotherapy: target the stroma to hit the tumor. Trends Mol Med 11:225CrossRefPubMed
39.
Zurück zum Zitat Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675CrossRefPubMed Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675CrossRefPubMed
40.
Zurück zum Zitat Katz G, Gazit R, Arnon TI, Gonen-Gross T, Tarcic G, Markel G, Gruda R, Achdout H, Drize O, Merims S, Mandelboim O (2004) MHC class I-independent recognition of NK-activating receptor KIR2DS4. J Immunol 173:1819PubMed Katz G, Gazit R, Arnon TI, Gonen-Gross T, Tarcic G, Markel G, Gruda R, Achdout H, Drize O, Merims S, Mandelboim O (2004) MHC class I-independent recognition of NK-activating receptor KIR2DS4. J Immunol 173:1819PubMed
42.
43.
Zurück zum Zitat Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK (2001) Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol 2:443PubMed Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK (2001) Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol 2:443PubMed
44.
Zurück zum Zitat Ljunggren HG, Karre K (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 11:237CrossRefPubMed Ljunggren HG, Karre K (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 11:237CrossRefPubMed
45.
Zurück zum Zitat Lopez-Botet M, Angulo A, Guma M (2004) Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. Tissue Antigens 63:195CrossRefPubMed Lopez-Botet M, Angulo A, Guma M (2004) Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. Tissue Antigens 63:195CrossRefPubMed
46.
Zurück zum Zitat Lopez-Botet M, Bellon T, Llano M, Navarro F, Garcia P, de Miguel M (2000) Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol 61:7CrossRefPubMed Lopez-Botet M, Bellon T, Llano M, Navarro F, Garcia P, de Miguel M (2000) Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol 61:7CrossRefPubMed
47.
Zurück zum Zitat Maio M, Altomonte M, Tatake R, Zeff RA, Ferrone S (1991) Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest 88:282PubMedCrossRef Maio M, Altomonte M, Tatake R, Zeff RA, Ferrone S (1991) Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest 88:282PubMedCrossRef
48.
Zurück zum Zitat Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A (2001) Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409:1055CrossRefPubMed Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A (2001) Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409:1055CrossRefPubMed
50.
Zurück zum Zitat Marin R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Jimenez P, Geraghty DE, Garrido F (2003) Analysis of HLA-E expression in human tumors. Immunogenetics 54:767PubMed Marin R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Jimenez P, Geraghty DE, Garrido F (2003) Analysis of HLA-E expression in human tumors. Immunogenetics 54:767PubMed
51.
Zurück zum Zitat Mathew PA, Chuang SS, Vaidya SV, Kumaresan PR, Boles KS, Pham HT (2004) The LLT1 receptor induces IFN-gamma production by human natural killer cells. Mol Immunol 40:1157CrossRefPubMed Mathew PA, Chuang SS, Vaidya SV, Kumaresan PR, Boles KS, Pham HT (2004) The LLT1 receptor induces IFN-gamma production by human natural killer cells. Mol Immunol 40:1157CrossRefPubMed
52.
Zurück zum Zitat Maxwell W, McDevitt J, Reid I, Sharpe I, Feighery C, Tanner WA, Emmons R, Monson JR (1993) Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma. Eur J Surg Oncol 19:265PubMed Maxwell W, McDevitt J, Reid I, Sharpe I, Feighery C, Tanner WA, Emmons R, Monson JR (1993) Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma. Eur J Surg Oncol 19:265PubMed
53.
Zurück zum Zitat Menier C, Riteau B, Carosella ED, Rouas-Freiss N (2002) MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int J Cancer 100:63CrossRefPubMed Menier C, Riteau B, Carosella ED, Rouas-Freiss N (2002) MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int J Cancer 100:63CrossRefPubMed
54.
Zurück zum Zitat Mingari MC, Pietra G, Moretta L (2005) Human cytolytic T lymphocytes expressing HLA class-I-specific inhibitory receptors. Curr Opin Immunol 17:312CrossRefPubMed Mingari MC, Pietra G, Moretta L (2005) Human cytolytic T lymphocytes expressing HLA class-I-specific inhibitory receptors. Curr Opin Immunol 17:312CrossRefPubMed
55.
Zurück zum Zitat Mingari MC, Ponte M, Bertone S, Schiavetti F, Vitale C, Bellomo R, Moretta A, Moretta L (1998) HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells. Proc Natl Acad Sci USA 95:1172CrossRefPubMed Mingari MC, Ponte M, Bertone S, Schiavetti F, Vitale C, Bellomo R, Moretta A, Moretta L (1998) HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells. Proc Natl Acad Sci USA 95:1172CrossRefPubMed
56.
Zurück zum Zitat Mingari MC, Ponte M, Vitale C, Bellomo R, Moretta L (2000) Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Hum Immunol 61:44CrossRefPubMed Mingari MC, Ponte M, Vitale C, Bellomo R, Moretta L (2000) Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Hum Immunol 61:44CrossRefPubMed
57.
Zurück zum Zitat Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L (2000) Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 21:228CrossRefPubMed Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L (2000) Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 21:228CrossRefPubMed
58.
Zurück zum Zitat Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197CrossRefPubMed Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197CrossRefPubMed
59.
Zurück zum Zitat Moretta A, Moretta L (1997) HLA class I specific inhibitory receptors. Curr Opin Immunol 9:694CrossRefPubMed Moretta A, Moretta L (1997) HLA class I specific inhibitory receptors. Curr Opin Immunol 9:694CrossRefPubMed
60.
Zurück zum Zitat Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R, Bottino C, Moretta L (1995) Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 182:875CrossRefPubMed Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R, Bottino C, Moretta L (1995) Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 182:875CrossRefPubMed
61.
Zurück zum Zitat Moretta A, Tambussi G, Bottino C, Tripodi G, Merli A, Ciccone E, Pantaleo G, Moretta L (1990) A novel surface antigen expressed by a subset of human CD3- CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function. J Exp Med 171:695CrossRefPubMed Moretta A, Tambussi G, Bottino C, Tripodi G, Merli A, Ciccone E, Pantaleo G, Moretta L (1990) A novel surface antigen expressed by a subset of human CD3- CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function. J Exp Med 171:695CrossRefPubMed
62.
Zurück zum Zitat Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R, Barbaresi M, Ciccone E, Moretta L (1993) P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 178:597CrossRefPubMed Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R, Barbaresi M, Ciccone E, Moretta L (1993) P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 178:597CrossRefPubMed
63.
Zurück zum Zitat Moretta L, Biassoni R, Bottino C, Mingari MC, Moretta A (2000) Human NK-cell receptors. Immunol Today 21:420CrossRefPubMed Moretta L, Biassoni R, Bottino C, Mingari MC, Moretta A (2000) Human NK-cell receptors. Immunol Today 21:420CrossRefPubMed
64.
Zurück zum Zitat Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A (2004) Different checkpoints in human NK-cell activation. Trends Immunol 25:670CrossRefPubMed Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A (2004) Different checkpoints in human NK-cell activation. Trends Immunol 25:670CrossRefPubMed
65.
Zurück zum Zitat Moretta L, Moretta A (2004) Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 23:255CrossRefPubMed Moretta L, Moretta A (2004) Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 23:255CrossRefPubMed
66.
Zurück zum Zitat Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A (2003) Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 63:2535PubMed Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A (2003) Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 63:2535PubMed
67.
Zurück zum Zitat Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, Ami K, Hiraide H, Sekine I (2001) Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 103:281CrossRefPubMed Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, Ami K, Hiraide H, Sekine I (2001) Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 103:281CrossRefPubMed
68.
Zurück zum Zitat Park SH, Kyin T, Bendelac A, Carnaud C (2003) The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J Immunol 170:1197PubMed Park SH, Kyin T, Bendelac A, Carnaud C (2003) The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J Immunol 170:1197PubMed
69.
Zurück zum Zitat Parmiani G, Rivoltini L, Andreola G, Carrabba M (2000) Cytokines in cancer therapy. Immunol Lett 74:41CrossRefPubMed Parmiani G, Rivoltini L, Andreola G, Carrabba M (2000) Cytokines in cancer therapy. Immunol Lett 74:41CrossRefPubMed
70.
Zurück zum Zitat Pawelec G (2004) Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol Immunother 53:262CrossRefPubMed Pawelec G (2004) Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol Immunother 53:262CrossRefPubMed
71.
Zurück zum Zitat Pawelec G, Wagner W, Adibzadeh M, Engel A (1999) T cell immunosenescence in vitro and in vivo. Exp Gerontol 34:419CrossRefPubMed Pawelec G, Wagner W, Adibzadeh M, Engel A (1999) T cell immunosenescence in vitro and in vivo. Exp Gerontol 34:419CrossRefPubMed
72.
Zurück zum Zitat Pedersen LO, Vetter CS, Mingari MC, Andersen MH, thor Straten P, Brocker EB, Becker JC (2002) Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report. J Invest Dermatol 118:595CrossRefPubMed Pedersen LO, Vetter CS, Mingari MC, Andersen MH, thor Straten P, Brocker EB, Becker JC (2002) Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report. J Invest Dermatol 118:595CrossRefPubMed
73.
Zurück zum Zitat Pende D, Accame L, Pareti L, Mazzocchi A, Moretta A, Parmiani G, Moretta L (1998) The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur J Immunol 28:2384CrossRefPubMed Pende D, Accame L, Pareti L, Mazzocchi A, Moretta A, Parmiani G, Moretta L (1998) The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur J Immunol 28:2384CrossRefPubMed
74.
Zurück zum Zitat Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A, Moretta L (2001) Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31:1076CrossRefPubMed Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A, Moretta L (2001) Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31:1076CrossRefPubMed
75.
Zurück zum Zitat Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62:6178PubMed Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62:6178PubMed
76.
Zurück zum Zitat Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P (2000) Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 164:1148PubMed Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P (2000) Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 164:1148PubMed
77.
Zurück zum Zitat Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN (2003) Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 22:3180CrossRefPubMed Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN (2003) Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 22:3180CrossRefPubMed
78.
Zurück zum Zitat Regunathan J, Chen Y, Wang D, Malarkannan S (2005) NKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors. Blood 105:233CrossRefPubMed Regunathan J, Chen Y, Wang D, Malarkannan S (2005) NKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors. Blood 105:233CrossRefPubMed
79.
Zurück zum Zitat Riteau B, Menier C, Khalil-Daher I, Martinozzi S, Pla M, Dausset J, Carosella ED, Rouas-Freiss N (2001) HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol 13:193CrossRefPubMed Riteau B, Menier C, Khalil-Daher I, Martinozzi S, Pla M, Dausset J, Carosella ED, Rouas-Freiss N (2001) HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol 13:193CrossRefPubMed
80.
Zurück zum Zitat Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA (1995) Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 55:3149PubMed Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA (1995) Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 55:3149PubMed
81.
Zurück zum Zitat Rodriguez T, Mendez R, Roberts CH, Ruiz-Cabello F, Dodi IA, Nevot MA, Paco L, Maleno I, Marsh SG, Pawelec G, Garrido F (2005) High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. Cancer Immunol Immunother 54:141CrossRefPubMed Rodriguez T, Mendez R, Roberts CH, Ruiz-Cabello F, Dodi IA, Nevot MA, Paco L, Maleno I, Marsh SG, Pawelec G, Garrido F (2005) High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. Cancer Immunol Immunother 54:141CrossRefPubMed
82.
Zurück zum Zitat Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, Lanier LL (2005) Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 175:7796PubMed Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, Lanier LL (2005) Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 175:7796PubMed
83.
Zurück zum Zitat Rufer N, Zippelius A, Batard P, Pittet MJ, Kurth I, Corthesy P, Cerottini JC, Leyvraz S, Roosnek E, Nabholz M, Romero P (2003) Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood 102:1779CrossRefPubMed Rufer N, Zippelius A, Batard P, Pittet MJ, Kurth I, Corthesy P, Cerottini JC, Leyvraz S, Roosnek E, Nabholz M, Romero P (2003) Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood 102:1779CrossRefPubMed
84.
Zurück zum Zitat Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A (2005) Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 17:211CrossRefPubMed Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A (2005) Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 17:211CrossRefPubMed
85.
86.
Zurück zum Zitat Salih HR, Rammensee HG, Steinle A (2002) Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169:4098PubMed Salih HR, Rammensee HG, Steinle A (2002) Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169:4098PubMed
87.
Zurück zum Zitat Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708CrossRefPubMed Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708CrossRefPubMed
88.
Zurück zum Zitat Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2:850CrossRefPubMed Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2:850CrossRefPubMed
89.
Zurück zum Zitat Snyder MR, Weyand CM, Goronzy JJ (2004) The double life of NK receptors: stimulation or co-stimulation? Trends Immunol 25:25CrossRefPubMed Snyder MR, Weyand CM, Goronzy JJ (2004) The double life of NK receptors: stimulation or co-stimulation? Trends Immunol 25:25CrossRefPubMed
90.
Zurück zum Zitat Speiser DE, Pittet MJ, Valmori D, Dunbar R, Rimoldi D, Lienard D, MacDonald HR, Cerottini JC, Cerundolo V, Romero P (1999) In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med 190:775CrossRefPubMed Speiser DE, Pittet MJ, Valmori D, Dunbar R, Rimoldi D, Lienard D, MacDonald HR, Cerottini JC, Cerundolo V, Romero P (1999) In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med 190:775CrossRefPubMed
91.
Zurück zum Zitat Speiser DE, Valmori D, Rimoldi D, Pittet MJ, Lienard D, Cerundolo V, MacDonald HR, Cerottini JC, Romero P (1999) CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol 29:1990CrossRefPubMed Speiser DE, Valmori D, Rimoldi D, Pittet MJ, Lienard D, Cerundolo V, MacDonald HR, Cerottini JC, Romero P (1999) CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol 29:1990CrossRefPubMed
92.
Zurück zum Zitat Tarazona R, Casado JG, DelaRosa O, Torre-Cisneros J, Villanueva JL, Sanchez B, Galiani MD, Gonzalez R, Solana R, Pena J (2002) Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 22:176CrossRefPubMed Tarazona R, Casado JG, DelaRosa O, Torre-Cisneros J, Villanueva JL, Sanchez B, Galiani MD, Gonzalez R, Solana R, Pena J (2002) Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 22:176CrossRefPubMed
93.
Zurück zum Zitat Tarazona R, Casado JG, Soto R, DelaRosa O, Peralbo E, Rioja L, Pena J, Solana R (2004) Expression of NK-associated receptors on cytotoxic T cells from melanoma patients: a two-edged sword? Cancer Immunol Immunother 53:911CrossRefPubMed Tarazona R, Casado JG, Soto R, DelaRosa O, Peralbo E, Rioja L, Pena J, Solana R (2004) Expression of NK-associated receptors on cytotoxic T cells from melanoma patients: a two-edged sword? Cancer Immunol Immunother 53:911CrossRefPubMed
94.
Zurück zum Zitat Tarazona R, DelaRosa O, Alonso C, Ostos B, Espejo J, Pena J, Solana R (2000) Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev 121:77CrossRefPubMed Tarazona R, DelaRosa O, Alonso C, Ostos B, Espejo J, Pena J, Solana R (2000) Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev 121:77CrossRefPubMed
95.
Zurück zum Zitat Tarazona R, DelaRosa O, Casado JG, Torre-Cisneros J, Villanueva JL, Galiani MD, Pena J, Solana R (2002) NK-associated receptors on CD8 T cells from treatment-naive HIV-infected individuals: defective expression of CD56. AIDS 16:197CrossRefPubMed Tarazona R, DelaRosa O, Casado JG, Torre-Cisneros J, Villanueva JL, Galiani MD, Pena J, Solana R (2002) NK-associated receptors on CD8 T cells from treatment-naive HIV-infected individuals: defective expression of CD56. AIDS 16:197CrossRefPubMed
96.
Zurück zum Zitat Ugolini S, Arpin C, Anfossi N, Walzer T, Cambiaggi A, Forster R, Lipp M, Toes RE, Melief CJ, Marvel J, Vivier E (2001) Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells. Nat Immunol 2:430CrossRefPubMed Ugolini S, Arpin C, Anfossi N, Walzer T, Cambiaggi A, Forster R, Lipp M, Toes RE, Melief CJ, Marvel J, Vivier E (2001) Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells. Nat Immunol 2:430CrossRefPubMed
97.
Zurück zum Zitat Ugolini S, Vivier E (2000) Regulation of T cell function by NK cell receptors for classical MHC class I molecules. Curr Opin Immunol 12:295CrossRefPubMed Ugolini S, Vivier E (2000) Regulation of T cell function by NK cell receptors for classical MHC class I molecules. Curr Opin Immunol 12:295CrossRefPubMed
98.
Zurück zum Zitat Ugurel S, Reinhold U, Tilgen W (2002) HLA-G in melanoma: a new strategy to escape from immunosurveillance? Onkologie 25:129CrossRefPubMed Ugurel S, Reinhold U, Tilgen W (2002) HLA-G in melanoma: a new strategy to escape from immunosurveillance? Onkologie 25:129CrossRefPubMed
99.
Zurück zum Zitat Vetter CS, thor Straten P, Terheyden P, Zeuthen J, Brocker EB, Becker JC (2000) Expression of CD94/NKG2 subtypes on tumor-infiltrating lymphocytes in primary and metastatic melanoma. J Invest Dermatol 114:941CrossRefPubMed Vetter CS, thor Straten P, Terheyden P, Zeuthen J, Brocker EB, Becker JC (2000) Expression of CD94/NKG2 subtypes on tumor-infiltrating lymphocytes in primary and metastatic melanoma. J Invest Dermatol 114:941CrossRefPubMed
100.
Zurück zum Zitat Vivier E, Anfossi N (2004) Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat Rev Immunol 4:190CrossRefPubMed Vivier E, Anfossi N (2004) Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat Rev Immunol 4:190CrossRefPubMed
101.
Zurück zum Zitat Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A (2005) Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther 12:516CrossRefPubMed Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A (2005) Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther 12:516CrossRefPubMed
103.
Zurück zum Zitat Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730CrossRefPubMed Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730CrossRefPubMed
104.
Zurück zum Zitat Yokoyama WM, Plougastel BF (2003) Immune functions encoded by the natural killer gene complex. Nat Rev Immunol 3:304CrossRefPubMed Yokoyama WM, Plougastel BF (2003) Immune functions encoded by the natural killer gene complex. Nat Rev Immunol 3:304CrossRefPubMed
105.
Zurück zum Zitat Yokoyama WM, Seaman WE (1993) The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex. Annu Rev Immunol 11:613PubMed Yokoyama WM, Seaman WE (1993) The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex. Annu Rev Immunol 11:613PubMed
106.
Zurück zum Zitat Young NT, Uhrberg M, Phillips JH, Lanier LL, Parham P (2001) Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL. J Immunol 166:3933PubMed Young NT, Uhrberg M, Phillips JH, Lanier LL, Parham P (2001) Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL. J Immunol 166:3933PubMed
Metadaten
Titel
Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands
verfasst von
Rafael Solana
Javier G. Casado
Elena Delgado
Olga DelaRosa
Juan Marín
Esther Durán
Graham Pawelec
Raquel Tarazona
Publikationsdatum
01.01.2007
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 1/2007
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0141-y

Weitere Artikel der Ausgabe 1/2007

Cancer Immunology, Immunotherapy 1/2007 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.